- 2008 Psychopharmacology Update
-
2007 Psychopharmacology Update - Expires September 30, 2008
Early Onset Bipolar Disorder: What Those in the Know, Know
A program brought to you by eAACAP.
 Bennett L. Leventhal, M.D. Project Director |
 Gabrielle A. Carlson, M.D. Chair |
Commercial Support
This activity is supported through educational grants from Bristol-Myers Squibb and Eli Lilly and Company.
Learning Objectives
At the conclusion of this continuing medical education activity, participants should be able to:
- Define early onset bipolar disorder.
- Describe how different sources of information contribute to the diagnostic process, i.e., how to elicit information, what should be elicited and from whom, and what difference it makes which assessment is used.
- Discuss the comorbidities of bipolar disorder, and the context of factors such as stress, family psychopathology, cognitive differences, and severity of illness.
- Identify several treatment approaches of bipolar disorder, and assess whether differing approaches lead to different ways of addressing treatment of mania and bipolar depression.
CME Credit
A maximum of 2.0 hours of Category 1 CME credit offered.
Alcohol and Other Substance Use Disorders Curriculum for Child and Adolescent Psychiatry Practitioners, Residents and Other Health Professionals
A program brought to you by eAACAP.
|
|
Commercial Support
This activity is supported through an educational grant from Shire US. Inc.
Learning Objectives
At the conclusion of this continuing medical education activity, participants should be able to:
- Identify similarities and differences between adolescents and adults with substance use disorders.
- Recognize the developmental risk factors and bidirectional impact of co-occuring psychiatric and substance use disorders, as well as identify evidence-based treatment for adolescent substance use disorder, conduct disorder, ADHD, depression and anxiety disorders.
- Understand the empirical bases for behavioral family therapies and be familiar with the MST and FBT models and their respective clinical approaches to treating adolescent substance abuse.
- Describe the symptoms, assessment, and treatment strategies for adolescent nicotine addiction.
- Identify family based strategies and procedures to reduce risk of adolescent substance use intake and enhance the substance use resistance skills of their patients.
CME Credit
Earn 5.5 hours of Category 1 CME credit.
Click here for more information.
2008 Psychopharmacology Update - Online CME Program
Successful Transition from Acute to Maintenance Psychopharmacological Treatment in Child and Adolescent Psychiatry
A program brought to you by eAACAP.
Commercial Support
This activity is supported through educational grant from Eli Lilly and Company.
Learning Objectives
At the conclusion of this continuing medical education activity, participants should be able to:
- Identify the guidelines for both acute and long term treatment of Tourette’s and tic disorders, and discuss the impact and treatment of psychiatric comorbid disorders.
- Explain rational medication treatment options for acute treatment of youth with major depressive disorder.
- Name the medications that have been approved by the FDA for treatment of acute mania in adults, adolescents, and children, and ways in which the differential diagnosis of mania is relevant to which medications used.
- Describe the degree of effectiveness in controlled studies of medications used to treat children and adolescents with ADHD, and identify the short-coming in our understanding of relapse prevention.
- Discuss the common endocrine complications of current psychopharmacological agents and how their manifestations and management vary during short and long term drug administration.
- Define various anxiety disorders and discuss the pharmacological treatments available for childhood anxiety disorders.
- Identify the three most common classes of medications used in the treatment of pervasive development disorders (PDDs) and the long-term effects of such medications.
CME Credit
A maximum of 13.5 hours of Category 1 CME credit offered.
2007 Psychopharmacology Update – Online CME Program
Developmental Aspects of Psychopharmacological Treatment in Children, Adolescents, and Adults
A program brought to you by eAACAP.
Expires September 30, 2008 - No CME credit will be offered after this date.
Commercial Support
This activity is supported through an educational grant from Eli Lilly and Company.
Learning Objectives
At the conclusion of this continuing medical education activity, participants should be able to:
- Discuss the evidence-based research on ADHD psychopharmacological treatments.
- Outline general guidelines for the use of sleep medications in pediatric insomnia.
- Describe how SSRIs work in both the maturing and matured brain, and discuss the recent studies involving the use of SSRIs.
- Identify symptom/behavior differences between mania as it presents in children, adolescents, and adults, and discuss the current evidence-based information about differences in bipolar medication treatment.
- Describe medication strategies for Obsessive Compulsive Disorder.
- Discuss the appropriate monitoring techniques to detect drug-related endocrine complications.
- Employ treatment strategies for Tourette Disorder and co-occurring conditions.
CME Credit
A maximum of 14 hours of Category 1 CME credit offered.
These courses are part of a continuing medical education series under the direction of the American Academy of Child and Adolescent Psychiatry's Institutes Subcommittee and eAACAP. The American Academy of Child and Adolescent Psychiatry is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
